Abstract-Mineralocorticoid receptor (MR) activation may be deleterious to the cardiovascular system, and MR antagonists improve morbidity and mortality of patients with heart failure. However, mineralocorticoid signaling in the heart remains largely unknown. Using a pan-genomic transcriptomic analysis, we identified neutrophil gelatinase-associated lipocalin (NGAL or lipocalin 2) as a strongly induced gene in the heart of mice with conditional and targeted MR overexpression in cardiomyocytes (whereas induction was low in glucocorticoid receptor-overexpressing mice). NGAL mRNA levels were enhanced after hormonal stimulation by the MR ligand aldosterone in cultured cardiac cells and in the heart of wild-type mice. Mineralocorticoid pathological challenge induced by nephrectomy/aldosterone/salt treatment upregulated NGAL expression in the heart and aorta and its plasma levels. We show evidence for MR binding to an NGAL promoter, providing a mechanism for NGAL regulation. We propose that NGAL may be a marker of mineralocorticoiddependent injury in the cardiovascular system in mice. (Aldo) is a main regulator of renal sodium reabsorption, with an overall effect on volemia and blood pressure. Aldo binds to the mineralocorticoid receptor (MR), a transcription factor of the nuclear receptor family present in the kidney.
I nappropriate mineralocorticoid signaling has been shown to play an important role in the progression of cardiovascular (CV) disease. Aldosterone (Aldo) is a main regulator of renal sodium reabsorption, with an overall effect on volemia and blood pressure. Aldo binds to the mineralocorticoid receptor (MR), a transcription factor of the nuclear receptor family present in the kidney. 1 Extrarenal pathophysiological effects of this hormone have been characterized, extending its actions to the CV system, the brain, the adipose tissue, the skin, and the eye. [2] [3] [4] [5] Inappropriate MR activation has been shown to promote cardiac fibrosis in experimental models 6, 7 The Randomized Aldactone Evaluation Study, 8 Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, 9 and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure 10 clinical trials have demonstrated that the addition of the MR antagonists spironolactone or eplerenone to standard care markedly reduced the overall and CV mortality in patients with left ventricular systolic dysfunction and mild or severe symptoms of chronic heart failure (HF) or with HF signs after acute myocardial infarction.
The molecular mechanisms of Aldo and MR activation in the CV system are not yet fully established. A better understanding of these mechanisms may unveil novel biotargets for pharmacological modulation of the signaling cascades induced by mineralocorticoids in CV diseases.
In this study we identified neutrophil gelatinase-associated lipocalin (NGAL) in a pan-genomic transcriptomic analysis performed on hearts of transgenic mice that overexpress the MR in cardiomyocytes. NGAL (lipocalin 2 or 24p3) is a 25-kDa glycoprotein belonging to the lipocalin superfamily. 11, 12 The cell-specific roles of NGAL remain elusive, but enhanced NGAL in tissues, plasma, or urine has been reported in several pathological states, such as kidney failure 13 and obesity, 14, 15 and many other situations. Increased systemic and myocardial expressions of NGAL have been observed in clinical and experimental HF. 16, 17 Hormonal regulation of NGAL expression has not been investigated. Here we document NGAL induction after mineralocorticoid challenge, in vivo in the mouse heart and ex vivo in cultured cells.
Methods

Animals
The use of mice was in accordance with the guidelines of the European Community and approved by our institutional animal care and use committees. For conditional MR or glucocorticoid receptor (GR) overexpression in cardiomyocytes, the previously described double-transgenic MRcardio (␣-myosin heavy chain-tetracyclin transactivator/tetracyclin response element [tTA/tetO]-human MR) 18 and GRcardio mice (␣-myosin heavy chain-tTA/tetO-human GR) 19 were used and compared with their control littermates.
Wild-type mice were treated with Aldo alone (low or high doses) or submitted to nephrectomy/Aldo/salt treatment (NAS) as described in the supplementary Methods section (please see the online-only Data Supplement). MR antagonists used in vivo were either potassium canrenoate (30 mg/kg of body weight [BW] per day in the drinking water) for MRcardio or NAS mice or spironolactone (200 mg/kg of BW per day in the drinking water) for mice with chronic Aldo infusion.
Cell Culture
Reagents are from Sigma-Aldrich (Saint-Quentin Fallavier, France) unless specified. H9C2/MR ϩ cells, a clonal cell line of cardiomyocytes derived from the embryonic rat ventricle and stably expressing the MR (kindly provided by A. Naray-Fejes-Toth, Dartmouth School of Medicine, Lebanon, NH) were grown as described. 20 Cells were treated with Aldo, corticosterone, the GR antagonist RU38486, or the MR antagonist RU28318 (Tocris Biosciences, Bristol, United Kingdom), as indicated in the legend of Figure 3 .
HL-1 cells (kindly provided by W. C. Claycomb, Louisiana State University Health Sciences Center, New Orleans, LA), an immortalized cell line derived from neonatal mouse cardiac myocytes, were cultured as described 21 and transiently transfected with a mouse MR-expressing plasmid. 22 Cell treatments are indicated in legends of Figure 4 . Cell transfection and chromatin immunoprecipitation are described in the supplementary Methods section.
Primary mouse aortic endothelial cells and primary mouse vascular smooth muscle cells derived from 8-to 10-week-old mice were isolated under sterile conditions as described. 23, 24 Endothelial cells were used at passages 2 to 3 and smooth muscle cells at passages 4 to 7. After 24 hours in serum-free medium, cells were incubated as indicated in legends of Figure 2 .
Cell Biology
Real-time PCR, Western blot, immunolocalization, and measurements of plasma levels of NGAL are indicated in the supplementary Methods section.
Statistical Analyses
Results are provided as meanϮSEM. The nonparametric MannWhitney U test was used to assess statistical differences between 2 experimental groups. Differences among Ͼ2 experimental conditions were tested by the ANOVA 1-way analysis followed by the Newman-Keuls test; PϽ0.05 was considered significant.
Results
Cardiac NGAL Expression Is Enhanced After MR Overexpression in Cardiomyocytes
A pan-genomic transcriptomic analysis on hearts of doubletransgenic mice that overexpress the MR in cardiomyocytes only (MRcardio mice) identified NGAL as a gene highly induced in the heart of MRcardio mice; the induction is essentially MR dependent and not GR dependent, because cardiac NGAL mRNA was strongly enhanced in MRcardio mice (Ϸ150 fold compared with the control littermates), whereas GR overexpression (in GRcardio mice) led to a much smaller (Ϸ5-fold) increase in NGAL mRNA ( Figure  1A) . Treatment of MRcardio mice with the MR antagonist potassium canrenoate reduced noticeably the NGAL cardiac levels, which were fully suppressed when mice were treated with doxycycline, that prevents transgene (MR) expression ( Figure 1A ). The MR-dependent induction of NGAL in the heart of MRcardio mice was also evident at the protein level, as measured by Western blot ( Figure 1B ). Immunolocalization of NGAL was negative in the heart from control mice and showed signal over cardiomyocytes of MRcardio mice ( Figure 
Increase in NGAL Expression After In Vivo Aldo Administration
Acute administration of Aldo (1 mg/kg of BW) induced cardiac NGAL expression 6 hours later (Figure 2A ). Chronic infusion of Aldo (1 mg/kg of BW per day for 4 weeks) induced a 2-fold increase in cardiac NGAL expression, an effect prevented by coadministration of the MR antagonist spironolactone ( Figure 2B ). Of note, in the mouse, infusion with Aldo alone at low concentrations (60 g/kg of BW per day) had no effect on cardiac NGAL expression ( Figure 2C ). The NAS model is a classic model of mineralocorticoid stress that associates mineralocorticoid administration on top of salt excess and reduced renal mass. We found that NGAL mRNA expression was increased in the heart of mice with NAS challenge, whereas nephrectomy alone, Aldo alone, or excess salt intake alone had no effect ( Figure 2C ). Because NGAL may be secreted, its plasma concentration was estimated in mice challenged with NAS treatment followed by MR antagonism. Four weeks of NAS challenge enhanced plasma NGAL levels, which returned to low values when mice were treated by an MR antagonist ( Figure 2D ). NAS challenge also enhanced by 2.5-fold NGAL mRNA expression in the aorta (data not shown). Immunolocalization experiments showed that NAS challenge led to clear NGAL signal over large cardiac vessels, whereas cardiomyocytes were barely positive; small arterioles and capillaries were negative ( Figure 2E ). Mineralocorticoid sensitivity of vascular NGAL expression was evidenced on primary cultures of aortic endothelial and smooth muscle cells: Aldo upregulated 
NGAL Is an Aldo/MR Target Gene in Cultured Cardiac Cells
To distinguish consequences of enhanced MR signaling from long-term cardiac adaptation to chronic MR activation, we measured NGAL expression in a rat cardiomyocyte cell line stably transfected with the MR (H9C2/MR ϩ cells). Aldo induced NGAL mRNA expression after 24-hour incubation, in a dose-dependent manner ( Figure 3A and 3B) . Cells treated by corticosterone ( Figure 3C ) or Aldo ( Figure 3D ) exhibited MR-specific enhanced NGAL mRNA ( Figure 3D ) and protein ( Figure 3E ) expression that was prevented by coincubation with the MR antagonist RU28318, whereas the GR antagonist RU28486 was ineffective ( Figure 3C through 3E) . Thus, NGAL is upregulated by both MR-Aldo and MRcorticosterone complexes in this cell context.
To evaluate the mechanism of NGAL regulation by MR activation, we used the mouse cardiomyocyte cell line HL-1 cells that do not express detectable levels of endogenous MR activity 22 and that were transiently transfected with mouse MR. Aldo produced a 6-fold increase in NGAL mRNA levels in HL-1 cells transfected with mouse MR but not in HL-1 cells transfected with empty vector (Figure 4A ). Cotransfection of mouse MR and NGAL-luciferase reporter construct (using the Ϫ794 to ϩ36 NGAL promoter region) that contains a hormone response element ( Figure 4B ), followed by Aldo treatment, resulted in a 4-fold increase in luciferase activity ( Figure 4C ) that was blocked by the MR antagonist spironolactone ( Figure 4C ). When the hormone response element was deleted, no significant increase in luciferase activity on Aldo treatment was detected ( Figure 4C ). This suggests that MR binds to the hormone response element present in the Ϫ794 to ϩ36 NGAL promoter and that NGAL is an Aldo/MR responsive gene. Chromatin immunoprecipitation showed that the hormone response element-mediated Aldo/MR effect is a direct consequence of MR binding to this promoter element ( Figure 4D ). When MR was transfected, the NGAL promoter was enriched in the chromatin immunoprecipitation product by 4-fold. Aldo treatment produced further enrichment of the NGAL promoter (Յ11-fold), indicating increased binding of MR to the promoter. These data show that the MR directly controls NGAL expression in cardiomyocytes by binding to its promoter.
Discussion
Inappropriate or excessive MR activation is a hallmark of a number of CV diseases that may benefit from treatments with MR antagonists. In this study we have provided evidence that NGAL is a mineralocorticoid-target gene in the CV system. We have shown that NGAL is a cardiac gene with high differential expression between mice with conditional MR overexpression restricted to the cardiomyocytes and their littermate controls. MRcardio mice have 5-fold more cardiac MR than control mice, 20 an experimental situation reminiscent of the increase in cardiac MR expression reported in rodent HF and myocardial infarction 25, 26 ; cardiac NGAL expression is specifically increased by MR activation rather than by GR activation; NGAL appears to be a direct target of MR, because chromatin immunoprecipitation experiments demonstrated that the MR binds on the NGAL promoter, at least in the cardiomyocyte cellular context NGAL is also dependent on MR activation in vascular cells; and plasma NGAL is modulated by Aldo/salt and MR antagonism. Taken together, our results show that NGAL is a novel actor of the Aldo/MR signaling cascade. In the literature, induction of NGAL has been reported in the hearts of rats with autoimmune myocarditis 27 or myocardial infarction 17 ; NGAL immunoreactivity was also evidenced in the cardiomyocytes and in the aortic atherosclerotic plaque in a mouse model of atherosclerosis, whereas it was undetectable in normal mice. 28 NGAL may bind covalently to the matrix metalloproteinase 9, leading to its stabilization and increased activity. 29 Although it remains difficult to attribute a specific function to the different forms of NGAL, it is tempting to propose that the NGAL-matrix metalloproteinase 9 complex may be particularly relevant in the context of matrix remodeling, observed in CV diseases and also on experimental MR activation.
It is highly plausible that several factors contribute to determine NGAL expression levels, in physiological situations and in pathology. Of interest, it has been shown that nuclear factor B (NF-B) can directly enhance NGAL expression, as demonstrated in vascular smooth muscle cells. Interleukin 1␤ triggers binding of NF-B to the NGAL promoter. 30 Further analysis of induction of NGAL through the NF-B pathway was provided recently. 31 Cross-talk between nuclear receptors and NF-B has been reported. 32 In the literature, there are data that show transcriptional antagonism between the MR and NF-B. 33 Aldo also inhibited NF-B activation (leading to production of tumor necrosis factor-␣) in neutrophils, and the authors concluded that MR mediates anti-inflammatory effects in these cells when they interact with the endothelium. 34 Conversely, activation of NF-B by Aldo has been reported in renal collecting duct cells; however, this may not be a direct effect but rather an adaptative phenomenon to limit excessive Aldo signaling. 35 In cardiac cells, balance between MR and NF-B may regulate NGAL expression; this balance may be different after short-term and long-term situations and even more in a pathological context. Further experiments are needed to test such hypotheses, to understand how and why NGAL levels vary. Altogether, these data illustrate the complexity of NGAL regulation that is far from being elucidated.
NGAL/lipocalin 2 is expressed at low levels in normal tissues and highly in a number of situations with tissue injury, where its roles are multiple and not fully understood. NGAL/lipocalin 2 was initially identified as a critical component of innate immunity, limiting bacterial infection, through sequestration of iron. 37 Later on, this protein was shown to be a modulator of cell proliferation, differentiation, apoptosis, and more generally in the reaction to various stress factors. 38, 39 Its expression is strongly enhanced in response to renal tubular injury. It has been shown that NGAL may protect the kidney from failure after ischemia/reperfusion 40 ; conversely, it was reported that it may belong to a critical pathway leading to progression toward renal failure. 41 Extensive literature data have been provided to designate plasma and/or urinary NGAL levels as sensitive markers of early prediction of kidney injury and its outcomes in humans. 13 NGAL, as a biomarker of renal tubular damage, may also reflect renal consequences of cardiac impairment after cardiac surgery, myocardial infarction, or cardiorenal syndrome associated with HF. However, recent data suggest that cardiac NGAL and circulating NGAL levels may be altered by cardiac dysfunction, independent of renal dysfunction. 42 Plasma NGAL is high in patients with acute HF after myocardial infarction (Optimal Trial in Myocardial Infarction With the Angiotensin II Antagonist Losartan), 17 as well as in patients with chronic HF 17 or coronary heart disease 43 and in the atherosclerotic plaque. 28 We found that NGAL plasma concentration is enhanced on mineralocorticoid stress in mice (although it is difficult to determine the origin of plasma NGAL in the NAS model). Human trials should determine whether plasma NGAL correlates with circulating Aldo levels and MR antagonism in patients with HF.
Perspectives
We demonstrate in the present study that NGAL is upregulated by mineralocorticoids, through MR activation, in the CV system, where its cellular functions remain to be elucidated. Future studies should also determine whether the rise of plasma NGAL may serve as a biomarker of excessive MR activation in patients with HF, to select those who could benefit from treatment with MR antagonists.
